OMER at a glance
OMEROS CORP (OMER, SEC CIK 1285819) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as October 30, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding OMEROS CORP (OMER) shares worth $324.9 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Borges David J. on September 23, 2026 of 10,000 shares at $20.95 per share.
- In the last 90 days, OMER insiders reported 0 open-market purchases ($0) and 8 open-market sales ($1.6M) on Form 4, a net sale of $1.6M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 8 sells
- Net −$1.6M
- 13F holders
- 27 funds
- $324.9M · +2 vs prior quarter
- Latest 8-K
- Nov 16, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue $35.9M vs $0 YoY, following YARTEMLEA launch in January 2026
- Gross margin approximately 100% in Q3, reflecting low-cost pre-approval inventory
- YARTEMLEA: $35.9M net sales, 109 ordering accounts, up 49% from June 30
- Cash, equivalents and short-term investments $95.3M; operating cash flow $13.3M
- Q4 R&D and SG&A expected higher; EU authorization not expected after negative CHMP opinion
Risk Factors
- New market risk: $100.0 million share repurchase program may increase stock-price volatility
- Program discretion: repurchases may be suspended or terminated anytime, with $90.1 million remaining November 16, 2026
- Liquidity risk: repurchases could potentially reduce market liquidity for common stock
- Valuation risk: stock price may decline below repurchase prices, reducing shareholder value
AI summary of the OMER 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Omeros reported financial results for the three and nine months ended September 30, 2026
- Detailed financial figures and management commentary appear in Exhibit 99.1 accompanying the 8-K
Item EX-99.1: Item EX-99.1
- YARTEMLEA Q3 gross revenue $41.8M, up 29.6% sequentially, with net revenue $35.9M, supporting commercial momentum
- Positive operating cash flow $13.3M and cash plus short-term investments $95.3M, improving near-term funding capacity
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CEO Gregory Demopulos granted performance option for 500,000 shares, signaling retention focus and substantial potential dilution
- Exercise price $17.88, with four stock-price hurdles from $25.00 to $40.00 over a five-year performance period
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board expanded to nine directors with Joseph Schocken appointed effective August 12, 2026
- Schocken joins the Audit Committee, adding investment banking and public-company governance experience
AI summaries of OMER 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for OMER
Don't miss the next OMER filing
- Alerts as it files. A push when OMER files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut OMER, by share count.
- Ask anything. An AI agent that reads every OMER filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Demopulos Gregory A MD | A | Oct 28, 2026 | 500,000 | - |
| Borges David J. | M | Sep 23, 2026 | 10,000 | - |
| Borges David J. | Sell | Sep 23, 2026 | 10,000 | $20.95 |
| Borges David J. | M | Sep 23, 2026 | 10,000 | $15.58 |
| Borges David J. | Sell | Sep 22, 2026 | 10,000 | $20.95 |
| Borges David J. | M | Sep 22, 2026 | 5,000 | $2.94 |
| Borges David J. | M | Sep 22, 2026 | 5,000 | - |
| Borges David J. | M | Sep 22, 2026 | 5,000 | $3.93 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$164.5M | -$169.3M | -$122.8M |
| Net Income | -$117.8M | -$156.8M | -$3.4M |
| Balance Sheet | |||
| Total Assets | $378.3M | $277.1M | $325.6M |
| Equity | -$25.0M | -$182.6M | -$121.2M |
| ROE | 471.6% | 85.9% | 2.8% |
| Per Share | |||
| EPS | - | $-2.70 | $-0.05 |
| Cash Flow | |||
| Operating CF | $74.7M | -$148.8M | -$116.1M |
| CapEx | $426K | $165K | $65K |
Source: XBRL data in OMEROS CORP (OMER)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate OMER share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 27 | $324.9M |
| Q2 2026 | 25 | $155.1M |
| Q1 2026 | 28 | $151.1M |
| Q4 2025 | 24 | $267.7M |
| Q3 2025 | 24 | $70.3M |
| Q2 2025 | 25 | $44.7M |
| Q1 2025 | 23 | $77.9M |
| Q4 2024 | 19 | $76.4M |
- Citadel Advisors LLC+540.4K (+631%)
- Morgan Stanley+409.5K (+104%)
- Bank of America Corp+338.9K (+175%)
- Goldman Sachs Group+238.0K (+152%)
- Prudential Financial+58.0K (+137%)
- Invesco Ltd−537.6K (-72%)
- Millennium Management−129.9K (-38%)
- Two Sigma Investments−117.8K (-29%)
- State Street Corp−79.0K (-3%)
- Wells Fargo & Co−53.1K (-34%)
- Franklin Resources+26.8K
- D.E. Shaw & Co+13.1K
- Raymond James Financial+11.1K
- FMR LLC (Fidelity)−15.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 195 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
OMER filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 16, 2026 | - | Analysis | - |
| 10-Q | Nov 16, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 30, 2026 | - | - | - |
| 8-K | Oct 30, 2026 | - | Analysis | - |
| 4 | Sep 24, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 24, 2026 | - | - | - |
| 4 | Jul 24, 2026 | - | - | - |
| 4 | Jul 24, 2026 | - | - | - |
| 8-K | Jul 20, 2026 | - | Analysis | - |
| 8-K | Jul 6, 2026 | - | Analysis | - |
| 8-K | Jun 25, 2026 | - | Analysis | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
OMER SEC filings: frequently asked questions
Are OMER insiders buying or selling?
In the last 90 days, OMEROS CORP (OMER) officers, directors and 10% owners reported no open-market purchases and 8 open-market sales worth $1.6 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold OMER stock?
As of September 30, 2026, the largest OMEROS CORP (OMER) holders among the 13F filers tracked by SignalX were BlackRock ($115.1 million), Vanguard Capital Management LLC ($58.2 million), State Street Corp ($42.7 million), Vanguard Portfolio Management LLC ($18.4 million), Morgan Stanley ($15.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did OMER report in its latest 8-K?
OMEROS CORP (OMER) filed an 8-K on November 16, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Omeros reported financial results for the three and nine months ended September 30, 2026.
What are the latest OMER SEC filings?
OMEROS CORP (OMER) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on October 30, 2026.
What is OMER's SEC CIK number?
OMEROS CORP (OMER)'s SEC Central Index Key (CIK) is 1285819. EDGAR lists every OMER filing under that number.
Ask anything about OMER
The research agent reads OMER's filings, financials, insider trades and 13F holders, then answers with sources.